Articles tagged with Prostate Cancer
A new drug combination has shown promising results in delaying the progression of advanced prostate cancer in patients with specific genetic mutations. The trial, led by UCL researchers, found that combining niraparib with standard treatment delayed disease recurrence and improved survival rates for eligible patients.
The ASPIRE trial is a Phase III clinical study investigating whether adding chemotherapy to standard treatments can extend survival in men with advanced prostate cancer. The trial aims to determine the effectiveness of combining docetaxel with hormone therapy and apalutamide.
A study found that stereotactic body radiotherapy (SBRT) after prostate surgery is safe and effective in preventing cancer recurrence, with low side effects and manageable treatment. The results suggest SBRT may be a faster and simpler option for men at risk of recurrent prostate cancer.
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
A large phase III trial found that stereotactic body radiation therapy (SBRT) preserves quality of life, with fewer declines in bowel and urinary functioning. However, SBRT does not outperform standard radiation therapy for disease-free survival, with higher rates of biochemical failure and rising PSA after treatment.
Dr. Amar Kishan has been recognized for his groundbreaking research on radiation treatments for genitourinary system cancers. He is the recipient of the 2025 Steven A. Leibel Memorial Award, presented by ASTRO and ABR Foundation.
The NRG-GU005 clinical study shows that SBRT significantly improves bowel health-related quality of life in patients with localized immediate risk prostate cancer. However, no significant improvement was seen for urinary HRQOL, and SBRT was not superior to IMRT in terms of distant-free survival.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
A new clinical trial found that adding a PSMA-targeting agent to stereotactic radiation therapy doubled progression-free survival in patients with limited metastatic prostate cancer. The study also showed that the treatment delayed hormone therapy by 24 months and improved local control.
A new PSMA-targeting radioligand therapy added to stereotactic body radiotherapy (SBRT) more than doubled progression-free survival in men with recurrent prostate cancer, delaying the start of hormone therapy by up to 24 months. The study found minimal side effects and identified biological markers that may predict treatment benefits.
Researchers from UCLA presented findings on targeted radioactive therapy, new SBRT approaches and advances in MRI- and 5DCT-guided imaging. The LUNAR clinical trial looked at adding a targeted therapy before ablative radiotherapy for men with recurrent prostate cancer.
Dr. Eggener brings extensive expertise in prostate and testicular cancer detection, diagnosis, and treatment to UCLA Health. He aims to improve prostate cancer detection and treatment through research.
The NRG Oncology PREDICT-RT study has completed patient accrual, evaluating intensified and de-intensified concurrent radiation regimens for high-risk prostate cancer patients. The study aims to improve quality of life and outcomes by tailoring treatments based on genomic risk scores.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
A new study found that Black men often view their primary-care providers as gatekeepers for prostate cancer screening, but are frequently dismissed from getting PSA tests. The study's lead author notes that PSA testing can catch the disease earlier and reduce mortality rates by up to 30% if done in the 40s rather than the 50s.
A recent study found that RAB26 is mainly expressed in luminal and basal/intermediate prostate cancer cells, correlating with advanced pathological stage and poor patient prognosis. RAB26 promotes proliferation, migration, and invasion of PCa cells while inhibiting apoptosis.
A new study published in JAMA finds biparametric magnetic resonance imaging (MRI) to be more efficient than multiparametric MRI for prostate cancer diagnosis. By adopting biparametric MRI, the global healthcare system could see a substantial increase in scanner throughput and cost reduction.
A quicker and cheaper two-part MRI scan is just as effective as the current 30-40 minute scan in detecting prostate cancer. The PRIME trial confirms that this streamlined approach can diagnose cancer at the same rate as a full three-part scan, cutting scan time to 15-20 minutes and reducing costs.
The ASTRO's 2025 Annual Meeting will feature pivotal studies in radiation medicine, highlighting advances in radiopharmaceutical therapy and new indications for low-dose radiation therapy. The meeting will also explore cutting-edge techniques for prostate, breast, lung, and other common cancers.
A new study from Memorial Sloan Kettering Cancer Center shows the Make-an-IMPACT program improves global access to genomic testing for pediatric cancer patients. The program helps develop an experimental antibody that shows promise against metastatic cancer. Researchers also shed light on the origins of ERG-driven prostate cancer and f...
A novel nomogram predicts survival probabilities for patients with both prostate cancer and secondary primary malignancies (SPMs). The study also reveals a significant causal relationship between prostate cancer and urothelial carcinoma, particularly bladder and upper tract cancers.
Researchers have developed a novel urine-based test to identify prostate cancer using biomarkers TTC3, H4C5, and EPCAM. The three-biomarker panel accurately detected prostate cancer 91% of the time and ruled out non-cancerous conditions 84% of the time in validation studies.
A recent survey by Ohio State University Comprehensive Cancer Center found that 80% of Americans are unaware of the lack of noticeable symptoms in early-stage prostate cancer. The disease is treatable if caught early, and regular screening is crucial.
Hong Kong Metropolitan University (HKMU) has achieved its first-ever technology licensing agreement with a UK-based healthcare company. The know-how licensing agreement is for a non-invasive electrochemical screening technology that offers a promising method for early detection of prostate cancer through a simple urine test.
Researchers at Uppsala University have developed an AI system that can detect subtle tissue changes indicative of prostate cancer, missing it from human pathologists. The study found the AI detected cancers in over 80% of cases where pathologists missed them.
A new 'dual-mode' tracer agent shows promise in helping surgeons image and plan prostate cancer procedures while also providing guided surgery with real-time radiation detection. The tracer targets PSMA, a protein highly expressed on prostate cancer cells, offering high-resolution visual guidance and targeted radiation density detection.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A new study from Denmark shows that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to those who do not. This research confirms that PSMA PET/CT is a valuable tool for identifying patients likely to benefit from salvage radiotherapy, potentially ...
Motolani Adedipe, a University of Oklahoma professor, has been awarded a Fulbright to conduct research on improving quality of life for prostate cancer survivors in South Korea. Her mixed-methods approach focuses on community engagement and will inform digital health innovation.
Researchers found that RSPO2 amplification is associated with poor outcomes in PC patients and promotes genes and signaling pathways associated with aggressive PC. The study highlights RSPO2 as a key driver of disease progression and opens new possibilities for treatment strategies.
This study used SILAC-based quantitative proteomics to investigate the impact of missense mutations on protein expression in prostate cancer versus healthy tissues. The results show that missense mutations correlate with changes in protein abundance, and specific mutations have deleterious effects on protein stability and function.
A new study found that one in six men with low-grade prostate cancer (GG1) actually have intermediate- or high-risk cancer when other clinical features are considered. This suggests that relying on biopsy grade alone can lead to underestimating disease risk and misclassifying individuals who may benefit from definitive treatment.
Recent AI-based models, such as Asian Prostate Cancer Artificial Intelligence and Galen Prostate, optimize screening and reduce unnecessary biopsies. These models use multimodal clinical parameters and convolutional neural networks to detect prostate cancer and identify aggressiveness of cancer cells.
A recent study by JAMA Network Open reveals racial differences in care quality among men with newly diagnosed prostate cancer. Black men had lower odds of overtreatment, suggesting better care, while having lower odds of confirmatory testing on active surveillance, indicating worse care.
Researchers have found that a lower dose of abiraterone acetate, 500 mg daily, is as effective in treating prostate cancer as the standard regimen, but with fewer side effects. The study involved nine men with metastatic prostate cancer and showed comparable cancer suppression through reduced PSA levels and hormone suppression.
Researchers at MURR have optimized Terbium-161 for radiopharmaceutical use, enabling targeted destruction of cancer cells with high-energy electrons. The breakthrough could add extra therapeutic effectiveness to existing treatments without requiring new drug development.
City of Hope research demonstrates a new drug combination that slows advanced prostate cancer growth without improving overall survival. A novel AI conversation tool helps scientists uncover gene-disease connections without programming expertise.
Researchers found that prostate cancer cells store fats in lipid droplets under low oxygen conditions, making them less vulnerable to ferroptosis. This adaptation allows cancer cells to evade therapies designed to trigger cell death.
A new study from Uppsala University found that most men with prostate cancer who receive recommended treatment have a good prognosis, with a lower risk of dying from prostate cancer than other causes. The study's findings highlight the importance of assessing a patient's life expectancy in choosing an appropriate treatment strategy.
A study of 62,839 people diagnosed with non-metastatic prostate cancer in Sweden found that those treated according to NCCN Guidelines were likely to survive their cancer for their remaining life-expectancy. Those with low- and intermediate-risk cancer were six times more likely to die of other causes than prostate cancer.
A new study from the University of Michigan Rogel Cancer Center identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. The researchers found that docetaxel could be a good option earlier on in patients whose tumor harbors a specific gene program linked to extreme no...
Researchers identify tumor-associated macrophages that shield tumors from attack and promote metastasis in advanced prostate cancer. Blocking these cells with anti-SPP1 treatment boosts the immune response, slowing cancer progression.
Sylvester researchers found that alcohol-related cancer deaths increased by nearly double from 1990 to 2021, primarily affecting men over 55. A new four-drug combination has been shown to be highly effective and safe in treating patients with newly diagnosed multiple myeloma.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
A dual-protective approach using Botox and an anti-nausea patch significantly reduces salivary gland toxicity in prostate cancer patients undergoing PSMA-targeted radiopharmaceutical therapy. This strategy led to a 30% decrease in PSMA uptake by the salivary glands without affecting the treatment's cancer-fighting efficacy.
Scientists at MSK found that certain metabolites play a key role in driving differentiation in stem cells, potentially leading to improved tissue regeneration and healing for conditions involving chronic inflammation. APOBEC3 enzymes were linked to breast cancer resistance and growth, with implications for treatment.
Researchers found that low-cost genetic testing methods can effectively detect BRCA2 and HOXB13 mutations linked to increased prostate cancer risk. These findings support the adoption of precision medicine in prostate cancer care, enabling better diagnosis and personalized treatment plans.
Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.
Researchers at CIC bioGUNE have made a significant breakthrough in understanding the most aggressive form of prostate cancer, revealing that it behaves differently from other types. The study shows that cancer cells use a unique 'language' to communicate with normal cells, altering their behavior and benefiting the tumor.
Researchers identified a novel region in AR that binds to PCNA, and developed a small peptide to mimic this region, blocking the AR-PCNA connection. This approach reduced cancer cell growth, particularly in patients with limited treatment options.
Researchers identified the PROX1 gene as an early driver of prostate cancer aggression, which leads to treatment-resistant tumors. The team found that a class of FDA-approved drugs, HDAC inhibitors, can disable PROX1 and reduce tumor survival in aggressive prostate cancer subtypes.
Acupuncture was found to be an effective treatment for nocturia in survivors of prostate cancer, reducing symptoms comparable to other medications while causing fewer side effects. The study suggests acupuncture may offer a new hope for managing this common issue affecting half of prostate cancer survivors.
Researchers from City of Hope will present novel cancer treatment approaches and combinations, including innovative combination therapies for breast, genitourinary, and gastrointestinal cancers. Additionally, they'll discuss the safety of readministering trastuzumab-deruxtecan to metastatic breast cancer patients with low-grade lung co...
Exosomes carry tumor-derived DNA, RNA, and proteins, enabling a liquid biopsy platform. They enhance diagnostic specificity and sensitivity, and play dual roles—mediating drug resistance and serving as therapeutic vehicles. Exosomal cargo predicts metastatic potential and survival.
The University of Texas MD Anderson Cancer Center has been awarded $21.4 million by CPRIT to support cancer research efforts and faculty recruitment. The institution is grateful for the continued funding, which will help advance future potential breakthroughs in cancer treatment.
Researchers at MD Anderson Cancer Center have made significant discoveries in three key areas of cancer care. In a study on sickle cell disease, the team found that the disorder can suppress immunity by altering DNA structure in CD8+ T cells, leading to potential strategies for improving immunotherapy responses. Meanwhile, a biomarker-...
Christopher Kane's appointment as ABU president reflects his commitment to excellence in patient care, groundbreaking research, and physician mentorship. As president, he will refine certification protocols and enhance the urologist experience.
The study found key differences in tumor biology between non-Hispanic Black and non-Hispanic white veterans, but similar survival outcomes when both groups had equal access to care. The research highlights the importance of broadening access to genomic tools and prioritizing equity in cancer treatment.
Researchers found that stereotactic body radiotherapy (SBRT) is as safe as conventional treatment, with similar side effects and quality of life. SBRT shortens treatment time and may have biological advantages in targeting prostate cancer.
A new AI-based method accurately sorts cancer patients into groups with similar characteristics before treatment and similar outcomes after treatment. The approach showed better performance than standard statistical and machine learning methods in predicting treatment outcomes from health record data.